Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Author Correction: Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson–Gilford progeria syndrome

The Original Article was published on 11 March 2021

Correction to: Nature Medicine https://doi.org/10.1038/s41591-021-01262-4, published online 11 March 2021.

In the version of this article initially published, the source of lonafarnib was not provided. This should be included as the second sentence of the Acknowledgements section, as follows: “Lonafarnib was provided by Merck through The Progeria Research Foundation’s Pre-Clinical Drug Supply Program.” The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tom Misteli.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Puttaraju, M., Jackson, M., Klein, S. et al. Author Correction: Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson–Gilford progeria syndrome. Nat Med 27, 1309 (2021). https://doi.org/10.1038/s41591-021-01415-5

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing